Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Operating Expenses (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Operating Expenses for 16 consecutive years, with $39.9 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 11.82% to $39.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $114.4 million through Dec 2025, up 23.94% year-over-year, with the annual reading at $114.4 million for FY2025, 23.94% up from the prior year.
  • Operating Expenses hit $39.9 million in Q4 2025 for Perspective Therapeutics, up from $28.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $45.2 million in Q4 2024 to a low of $2.1 million in Q1 2021.
  • Historically, Operating Expenses has averaged $14.4 million across 5 years, with a median of $10.3 million in 2023.
  • Biggest five-year swings in Operating Expenses: soared 276.41% in 2024 and later dropped 11.82% in 2025.
  • Year by year, Operating Expenses stood at $2.9 million in 2021, then skyrocketed by 96.88% to $5.6 million in 2022, then skyrocketed by 113.72% to $12.0 million in 2023, then skyrocketed by 276.41% to $45.2 million in 2024, then decreased by 11.82% to $39.9 million in 2025.
  • Business Quant data shows Operating Expenses for CATX at $39.9 million in Q4 2025, $28.1 million in Q3 2025, and $24.3 million in Q2 2025.